These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 26293665)

  • 1. SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.
    Okamoto K; Tsunematsu R; Tahira T; Sonoda K; Asanoma K; Yagi H; Yoneda T; Hayashi K; Wake N; Kato K
    BMC Med Genet; 2015 Aug; 16():67. PubMed ID: 26293665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of
    Helwa R; Gansmo LB; Bjørnslett M; Halle MK; Werner HMJ; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    Biomarkers; 2021 Jun; 26(4):302-308. PubMed ID: 33645339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
    Walsh CS; Miller CW; Karlan BY; Koeffler HP
    Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
    Knappskog S; Trovik J; Marcickiewicz J; Tingulstad S; Staff AC; ; Romundstad P; Hveem K; Vatten L; Salvesen HB; Lønning PE
    Eur J Cancer; 2012 Sep; 48(13):1988-96. PubMed ID: 22119201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between MDM2 SNP309 polymorphism and endometrial cancer risk in Polish women.
    Zając A; Stachowiak G; Pertyński T; Romanowicz H; Wilczyński J; Smolarz B
    Pol J Pathol; 2012 Dec; 63(4):278-83. PubMed ID: 23359199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
    Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
    Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms of p53 codon 72 and MDM2 promoter 309 and the risk of endometrial cancer.
    Nunobiki O; Ueda M; Yamamoto M; Toji E; Sato N; Izuma S; Okamoto Y; Torii K; Noda S
    Hum Cell; 2009 Nov; 22(4):101-6. PubMed ID: 19874399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
    Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    Gansmo LB; Bjørnslett M; Halle MK; Salvesen HB; Romundstad P; Hveem K; Vatten L; Dørum A; Lønning PE; Knappskog S
    BMC Cancer; 2017 Feb; 17(1):97. PubMed ID: 28158999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between MDM2 SNP309 and endometrial cancer risk: A PRISMA-compliant meta-analysis.
    Zou X; Zhang Y; Zhang L; Li J; Zhu C; Cheng Q; Zhou J; Chen Y
    Medicine (Baltimore); 2018 Dec; 97(49):e13273. PubMed ID: 30544386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
    Helwa R; Gansmo LB; Romundstad P; Hveem K; Vatten L; Ryan BM; Harris CC; Lønning PE; Knappskog S
    Sci Rep; 2016 Sep; 6():33153. PubMed ID: 27624283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
    Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
    Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
    Nan H; Qureshi AA; Hunter DJ; Han J
    Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
    Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
    Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.
    Peng Q; Mo C; Qin A; Lao X; Chen Z; Sui J; Wu J; Zhai L; Yang S; Qin X; Li S
    J Exp Clin Cancer Res; 2013 Nov; 32(1):85. PubMed ID: 24423195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 and its functional polymorphism SNP309 contribute to the development of esophageal carcinoma.
    Xiao FK; Guo S; Yang F; Zhao LS; Wang LD
    J Gene Med; 2019 May; 21(5):e3086. PubMed ID: 30861607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
    Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
    Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population.
    Wang M; Zhang Z; Zhu H; Fu G; Wang S; Wu D; Zhou J; Wei Q; Zhang Z
    Clin Cancer Res; 2008 Jun; 14(11):3633-40. PubMed ID: 18519798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.